Spinnaker Investment Group LLC Invests $519,000 in Teva Pharmaceutical Industries Ltd. $TEVA

Spinnaker Investment Group LLC bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, Holdings Channel.com reports. The firm bought 25,700 shares of the company’s stock, valued at approximately $519,000.

A number of other large investors have also added to or reduced their stakes in the company. Bourgeon Capital Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after buying an additional 363,252 shares in the last quarter. Amundi boosted its stake in Teva Pharmaceutical Industries by 18.5% in the first quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after buying an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd grew its position in Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after acquiring an additional 19,447 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 5.5% during the second quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after acquiring an additional 37,455 shares in the last quarter. Finally, Jump Financial LLC raised its stake in shares of Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after acquiring an additional 838,423 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 622,060 shares of company stock valued at $17,076,965 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Up 0.2%

NYSE TEVA opened at $30.39 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $30.56. The stock has a market capitalization of $34.86 billion, a PE ratio of 50.65, a PEG ratio of 1.81 and a beta of 0.67. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The business’s 50-day moving average is $24.44 and its 200 day moving average is $20.06.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target on TEVA to $35 and reiterated a “buy” rating, signaling Wall Street conviction in upside versus the current level. Goldman Sachs price target raise
• Positive Sentiment: Additional analyst support: JPMorgan, BofA and Barclays have recently increased targets/ratings (JPMorgan to $35, BofA to $32, Barclays initiating overweight), which likely helped lift sentiment and buying interest. Analyst notes
• Positive Sentiment: Teva’s U.S. affiliate and Alvotech reached a settlement and license with Regeneron setting a U.S. launch window for AVT06 (a proposed biosimilar to Eylea) in Q4 2026 (or earlier under certain conditions) — this reduces launch uncertainty and creates a clearer commercialization timeline. Alvotech settlement
• Neutral Sentiment: Institutional activity is mixed but notable: several funds increased stakes (e.g., Hudson Bay Capital bought more), supporting the view that institutions are accumulating at current levels. Institutional trading
• Neutral Sentiment: Coverage pieces from Zacks and The Motley Fool highlight TEVA as a value/long-term holding — these narrative articles may attract retail interest but are less likely to move price materially on their own. Zacks coverage
• Negative Sentiment: Insider selling: CAO Amir Weiss sold 12,300 shares and Director Roberto Mignone sold 77,400 shares in mid-December at ~\$30.20–30.24 — sizable disclosed sales that may concern some investors about near-term insider conviction. Insider sales

Analysts Set New Price Targets

TEVA has been the subject of a number of research reports. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 13th. The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Finally, Scotiabank assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.63.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.